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High-dose therapy followed by autologous stem cell transplantation is a standard treatment for refractory or relapsed high-grade lymphomas. Several conditioning regimen have been employed, BEAM being the most commonly used. Toxicity of BEAM regimen is generally low and cardiac toxicity is particularly unusual. 1 We describe a case of acute myocardial ischemia during BEAM therapy which was attributable to carmustine (BCNU).
Case report
A 52-year-old woman was referred to the hospital in September 1999 for treatment of an angioimmunoblastic lymphoma. Her past medical history was unremarkable. She had no cardiovascular risk factors. She was treated with two courses of CHOP. Because of progressive disease on CHOP therapy, treatment was switched to ESHAP. A complete remission was achieved after six courses. initiated, the patient's general condition was very good. Echocardiography performed 2 months earlier was normal, with a left ventricular ejection fraction of 56%. BCNU was infused at the standard dose (300 mg/m 2 on day 1). The only drugs coadministered were trimethoprim-sulfamethoxazole and ondansetron. Two hours after completion of the infusion, she complained of dyspnea and acute substernal chest pain with radiation to both arms. On clinical examination, bilateral crepitations were heard. Her blood pressure was unchanged. ECG disclosed ST segment elevation in leads V1, V2, V3 and T waves changes in all leads. The troponine level rose to 5.34 ng/ml (n Ͻ 0.06).
Echocardiography revealed diffuse cardiac dysfunction. After intravenous treatment with diuretics and nitroglycerin, the chest pain and dyspnea resolved in 12 h. Her ECG returned to baseline in 24 h. Coronary angiography performed 24 h after the first clinical symptoms, was normal. Thallium scintigraphy and repeat echocardiography, performed 1 week later, were normal with complete resolution of the abnormalities previously described. This allowed completion of the BEAM regimen at standard doses and peripheral stem cell transplantation. In November 2001, the patient was doing well with no recurrence of lymphoma, nor angina pectoris or any cardiovascular event.
Discussion
Here, a clear causal relationship between the BCNU and the occurrence of myocardial ischemia can be observed. The normal coronary angiography rules out the possibility of pre-existing coronary artery pathology. To our knowledge, this is the first such case reported after the BEAM regimen. Although exceptional, myocardial ischemia has been described after high-dose BCNU infusion. [2] [3] [4] In these cases, BCNU was given at higher doses than in the BEAM regimen (у600 mg/m 2 ), but unfortunately, none of these patients had had thorough cardiac investigations.
The mechanisms involved in the cardiac toxicity of BCNU are unknown. Several explanations have been proposed. Vasospasm of the coronary arteries as observed with 5FU has been suggested. A dramatic reduction in blood flow secondary to significant vasodilatation could be another explanation. Experimental data have shown that infusion of high-dose BCNU was associated with several cardiovascular modifications: fall in arterial blood pressure (reduction of 31 mm Hg in systolic pressure and of 26 mm Hg in diastolic pressure), tachycardia and intense flushing. 5 This suggests that in some cases these phenomena could be more severe leading to the occurrence of symptomatic cardiac disease. In several cases described in the literature, myocardial ischemia was associated with a fall in blood pressure. In one case complicated by fatal myocardial necrosis, a fall in blood pressure to 50 mm Hg was observed. 3 In our case, blood pressure remained stable, ruling out this mechanism.
Coadministration of high-dose carmustine and alkylating agents, especially cyclophosphamide as in the BEAC regimen, 6 could lead to significant cardiotoxicity. In these cases, it has been suggested that carmustine, by reducing the intracytoplasmic level of glutathione in the myocardial cells, could enhance the toxicity of alkylating agents. 7 In our case, such a mechanism can be excluded, myocardial ischemia having occurred before administration of any other drugs than carmustin. Finally, taking into account the normal coronary angiography and unchanged blood pressure, vasospasm appears to be the leading mechanism of acute myocardial ischemia in our patient. However, a direct cardiomyopathic effect of carmustin cannot be excluded.
In conclusion, clinicians should be aware of the potential cardiac toxicity of BCNU given during the BEAM regimen. It should be emphasized that this complication can be transient, allowing full completion of the planned high-dose therapy. Our patient received the entire BEAM regimen only 1 week after the acute myocardial ischemia.
